Otsuka/BMS Dasatinib Phase III Meets Primary Endpoint, Submit NDA Within 2010
This article was originally published in PharmAsia News
Executive Summary
Ostuka and Bristol Myers-Squibb announced results of Phase III study of Sprycel (dasatinib) for patients with chronic myeloid leukemia